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Background: Peak post-operative cardiac troponin T (cTnT) independently predicts
mid- and long-term outcome of cardiac surgery patients. A few studies however have
reported two peaks of cTnT over the first 48–72 h following myocardial reperfusion. The
aim of the current study was to better understand underlying reasons of these different
cTnT profiles and their possible relevance in terms of clinical outcome.
Methods: All consecutive adult cardiac surgical procedures performed with an
extra-corporeal circulation during a >6 years period were retrospectively evaluated.
Patients with a myocardial infarction (MI) <8 days were excluded. cTnT profile of
patients with at least one value ≥1 ng/mL value were categorized according to the time
occurrence of the peak value. Univariable and multivariable analysis were performed
to identify factors influencing early vs. late increase of cTnT values, and to verify the
correlation of early vs. late increase with clinical outcome.
Results: Data of 5,146 patients were retrieved from our prospectively managed registry.
From 953 with at least one cTnT value ≥1 ng/mL, peak occurred ≤6 h (n = 22), >6
to ≤12 h (n = 366), >12 to ≤18 h (n = 176), >18 to ≤24 h (171), >24 h (218). Age
(OR: 1.023; CI: 1.016–1.030) and isolated CABG (OR: 1.779; CI: 1.114–2.839) were
independent predictors of a late increase of cTnT over a limit of 1 ng/ml (p < 0.05),
whereas isolated valve procedures (OR: 0.685; CI: 0.471–0.998) and cross-clamp
duration (OR: 0.993; CI: 0.990–0.997) independently predicted an early elevation
(p < 0.05). Delayed elevation as opposed to early elevation correlated with a higher
rate of post-operative complications including MI (19.8 vs. 7.2%), new renal insufficiency
(16.3 vs. 6.7%), MACCE (32.0 vs. 15.5%), or death (7.4 vs. 4.4%).
Conclusion: Profile of cTnT elevation following cardiac surgery depends on patients’
intrinsic factors, type of surgery and duration of cross-clamp time. Delayed increase is
of higher clinically relevance than prompt post-operative elevation.
Keywords: cardiac surgery, CABG, troponin, cardiac biomarkers, complications
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INTRODUCTION
Biomarkers of myocardial injury invariably increase following
cardiac surgical interventions. Reasons essentially include the
direct surgical trauma to the cardiac tissue, the quality of the
myocardial protection, the type of surgery (1, 2), the duration
of ischemic cross clamp time (3–7), as well as conditions
related to the patient himself, such as the renal function (8–
11). Several studies have attempted to define biomarkers’ cut-off
values to predict outcome after cardiac surgery (1, 12–15). The
results appear however inconsistent, partially because of inter-
institutional variations in terms of overall patients’ management,
but also because of variations in methodological approaches. In
addition and maybe more importantly, these biomarkers are not
assessed in a continuous manner but only at certain time points.
In other words, our current practice does not allow to precisely
measure the peak of release. As a consequence, the use of cut-off
values can currently not be implemented in routine practice (16).
Recent guidelines on the diagnosis of perioperative myocardial
infarction (PMI) have even warned about misinterpretation (17,
18).
Cardiac troponin T (cTnT), because of its high sensitivity,
has lately been increasingly investigated as possible clinically
relevant marker of perioperative myocardial damage. But like
for other biomarkers, the difficulty in assessing its clinical
relevance comes from the fact that the timing of peak elevation
is not known. It has also been previously suggested that the
post-operative cTnT evolution is in fact bimodal with an early
peak occurring at around 6 h and a later peak occurring at
24–36 h (14, 19–21). Therefore, it would be advantageous to
better understand the factors that influence the profile of
post-operative cTnT evolution and possibly identify groups
of patients based on their expected peak of TnT release.
In addition, it is of interest to clarify if a certain cTnT
FIGURE 1 | Flowchart of patients’ selection.
elevation has the same clinical significance if it occurs rapidly
after the end of surgery of later during the post-operative
evolution.
In the current analysis of a prospectively collected population
of several thousands of cardiac surgery patients, we first intended
to characterize the post-operative profiles of cTnT evolution
and verify their possible dependence on patients- or surgery-
related factors. Additionally, we aimed at evaluating the clinical
relevance of these profiles in terms of complications, such as PMI,
stroke and death.
METHODS
Study Design and Patients Population
Retrospective single center study including all consecutive
adult patients undergoing a cardiac surgery procedure, between
September 2008 and December 2014, and identified from a
prospectively updated registry (Intellect 1.7, Dendrite Clinical
Systems, Henley-on-Thames, UK). TAVIs, heart transplantation,
procedures related to a cardiac assist system, isolated septal
procedures as well as other procedures, such as trauma,
embolectomy, pace-makers were excluded. For the sake of
homogeneity of the study groups and because isolated CABG
procedures are practically always performed with a mini extra-
corporeal circuit (MECC) in our institution, the few CABG
procedures performed with regular ECC or off-pump were
excluded. Finally, patients with a myocardial infarction (MI)
diagnosed <8 days before surgery were also excluded in order
to guarantee a normal basal cTnT level (Figure 1). The cantonal
ethics committee approved the current analysis as part of
our regularly performed quality control. All patients provided
informed consent regarding the collection of their data in our
registry and their pseudonymization before analysis. All raw
data supporting the conclusions of this manuscript can be made
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available by the authors, without undue reservation, to any
qualified researcher.
Surgical Procedures
Surgical procedures were standardized and performed typically
via a full sternotomy using a mini extracorporeal circulation
(MECC) for isolated CABG or a standard ECC for other
procedures, and moderate systemic hypothermia (32◦C). A
single shot low volume (100ml) cardioplegia (CardioplexolTM,
Laboratory Dr. G. Bichsel AG, Unterseen, Switzerland) was used
for isolated CABG procedures and repeated after 45–60min
in case of prolonged cross-clamp time. In other procedures,
the cardiac arrest was induced with 100ml CardioplexolTM and
followed every 20min with blood cardioplegia. Anesthesia was
also standardized and included the use of fentanyl, midazolam
and isoflurane.
Biomarkers Assessment
cTnT and CK-MB were routinely assessed 2–3 times during the
first 24 post-operative hours. If clinically indicated, cTnT was
further followed until the values started decreasing. Both TnT
and CK-MB were measured using an electrochemoluminescent
enzyme immunoassay on a Modular analytics E170 platform
(Roche Diagnostics, Mannheim, Germany). The upper limit of
normal was 0.014 ng/ml for the cTnT assay. For the purpose of
the study, the time of cTnT assessment was calculated from the
time at the end of the cardiopulmonary bypass and peak values
of each patient were then categorized in one of the following
categories: ≤6, >6 to ≤12, >12 to ≤18, >18 to ≤24, >24 h.
Unfortunately, cTnT was not systematically recorded prior to
surgery and a baseline value cannot be provided.
Data Acquisition and Definitions
All variables were retrieved from our institutional prospectively
maintained electronic registry, checked for completeness and
plausibility by two independent data managers, and if needed
completed or corrected with the aid of clinical records. The
diagnosis of a perioperative MI was made according to the
Third Universal Definition of Myocardial Infarction and the
SYNTAX trial as previously described (22). MACCE, major
adverse cardiovascular or cerebrovascular event, was defined as
a composite of all-cause mortality, MI, or stroke. Stroke was
defined by episodes of neurological dysfunction related to a focal
cerebral infarction that was confirmed by imaging. A new renal
insufficiency was defined by a new need of dialysis or, in patients
with preoperative creatinine <2 mg/dl, by a post-operative value
of creatinine that increased above 2 mg/dl and reached at least
twice the preoperative value.
Statistics
Continuous variables are summarized as mean ± SD if normally
distributed or as geometric mean with reference range, and
comparisons were made using linear or Poisson regression,
respectively. Dichotomous variables are expressed in absolute
numbers and percentages, and comparisons were made using
Fishers exact test. Non-parametric tests for trend were used
to assess the relationships between the five different time
intervals with respect to pre-, intra-, and post-operative data.
Multivariable logistic regression modeling was used to assess
independent associations between predictors and the period of
peak cTnT occurrence. All tests were two-sided and p < 0.05
were considered statistically significant. All statistical analysis
were performedwith Stata (version 12, Stat Corp, College Station,
Texas, USA).
RESULTS
A total of 6,545 patients were considered (Figure 1) from which
1,399 were excluded, mostly due to a recent MI (n = 758;
11.6%). The study group consisted then of 5,146 patients
of whom 953 (18.5%) presented at least one post-operative
cTnT value ≥1 ng/mL. The characteristics of these patients and
their difference with those whose cTnT value remained under
1 ng/ml are presented in Table 1A (patients characteristics),
Table 1B (procedure characteristics), and Table 1C (post-
operative outcomes).
The profile of cTnT evolution critically varied depending on
the period when the peak occurred (Figure 2). When considering
TABLE 1A | Characteristics of patients with elevated vs. “normal” post-operative
cTnT values.
cTnT <1ng/mL
(n = 4,193)
cTnT ≥1ng/mL
(n = 953)
p
Age (y) 66.0 ± 11.6 65.0 ± 12.9 0.020
Female gender (n, %) 1,129 (26.9) 299 (31.4) 0.006
Body mass index (kg/m2) 27.5 ± 6.8 27.0 ± 7.8 0.088
Diabetes (n, %) 880 (21.0) 177 (18.6) 0.000
Insulin therapy (n, %) 288 (6.9) 72 (7.6) 0.045
Current smoker (n, %) 2,220 (52.9) 460 (48.3) 0.000
Hypertension (n, %) 3,103 (74.0) 680 (71.4) 0.002
Dyslipidemia (n, %) 2,887 (68.9) 534 (56.0) 0.000
Previous PCI (n, %) 506 (12.1) 89 (9.3) 0.032
Previous cardiac surgery (n, %) 238 (5.7) 129 (13.5) 0.006
Last pre-operative creatinine (µmol/L) 87.2 ± 43.8 107.7 ± 96.9 0.000
Number if diseased cor. art. 0.000
0 coronary artery disease (n, %) 1,753 (41.8) 526 (55.2)
1 coronary artery disease (n, %) 287 (6.8) 68 (7.1)
2 coronary artery disease (n, %) 454 (10.8) 80 (8.4)
3 coronary artery disease (n, %) 1,699 (40.5) 279 (29.3)
Left main coronary artery disease (n, %) 442 (10.5) 63 (6.6) 0.049
Ejection fraction (n, %) 58.2 ± 11.6 56.5 ± 11.7 0.000
CCS III or IV (n, %) 742 (17.7) 141 (14.8) 0.032
NYHA III or IV (n, %) 1,051 (25.1) 343 (36.0) 0.000
Urgency 0.000
Emergency (n, %) 235 (5.6) 133 (14.0)
Urgent (n, %) 359 (8.6) 92 (9.7)
Logistic EuroSCORE 8.4 ± 11.1 14.8 ± 17.5 0.000
PCI, percutaneous coronary intervention; CCS, Canadian Cardiovascular Society
classification for angina pectoris; NYHA, New York Heart Association classification for
cardiac insufficiency.
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TABLE 1B | Procedure characteristics of patients with elevated vs. “normal”
post-operative cTnT values.
cTnT <1ng/mL
(n = 4,193)
cTnT ≥1ng/mL
(n = 953)
p
Number of distal anastomoses 2.8 ± 1.4 2.6 ± 1.6 0.000
Duration of operation (min) 209.9 ± 60.6 259.5 ± 88.9 0.000
ECC time (min) 88.8 ± 37.8 137.2 ± 61.1 0.000
Cross clamp time (min) 59.6 ± 27.4 89.9 ± 40.3 0.000
Defibrillation (n, %) 968 (23.1) 346 (36.3) 0.000
Grouping of operations: 0.000
Stand. isol. CABG (n, %) 1,658 (39.5) 164 (17.2)
CABG & valve (n, %) 586 (14.0) 192 (20.1)
Isol. aortic valve (n, %) 715 (17.1) 89 (9.3)
Isol. mitral valve (n, %) 250 (6.0) 96 (10.1)
Other (n, %) 984 (23.5) 412 (43.2)
CABG, coronary artery bypass grafting; ECC, extra corporeal circulation.
TABLE 1C | Post-operative outcomes of patients with elevated vs. “normal”
post-operative cTnT values.
cTnT <1ng/mL
(n = 4,193)
cTnT ≥1ng/mL
(n = 953)
p
Max. cTnT value (ng/mL)* 0.4 (0.4–0.4) 1.9 (1.8–2.0) 0.000
Max. CK-MB value (µg/L)* 16.0 (15.8–16.3) 56.4 (53.3–59.6) 0.000
Myocardial infarction (n, %) 13 (0.3) 140 (14.7) 0.000
Resuscitation (n, %) 20 (0.5) 38 (4.0) 0.000
Stroke (n, %) 135 (3.2) 75 (7.9) 0.000
Death (n, %) 24 (0.6) 59 (6.2) 0.000
MACCE (n, %) 165 (3.9) 241 (25.3) 0.000
ICU stay (d)* 1.2 (1.2–1.2) 1.7 (1.6–1.8) 0.000
ICU stay >48 h (n, %) 581 (13.9) 338 (35.5) 0.000
New AF (n, %) 1,002 (23.9) 248 (26.0) 0.130
Max. creatinine value (µmol/L)* 84.2 (83.2–85.2) 100.2
(96.9–103.6)
0.000
New renal insufficiency (n, %) 121 (2.9) 118 (12.4) 0.000
Length of stay (d)* 8.8 (8.7–8.9) 11.2 (10.7–11.7) 0.000
1 year mortality (n, %) 79 (1.9) 82 (8.6) 0.000
Mortality during FU (n, %) 168 (4.0) 114 (12.0) 0.000
*Calculations are based on the geometric mean and reference ranges. MACCE, major
adverse cardiovascular or cerebrovascular event (as a composite of all-cause mortality,
myocardial infarction, or stroke); ICU, intensive care unit.
only patients with at least one value ≥1 ng/mL, a few patients’
(Table 2A) and procedures’ (Table 2B) characteristics also
significantly varied with the period of cTnT peak occurrence. Age,
diabetes, preoperative renal function, coronary artery disease
and a history of previous cardiac intervention were all intrinsic
parameters that significantly differed between patients with an
early vs. late elevation of cTnT. In addition, isolated CABG,
isolated valve procedures and prolonged ECC are operative
parameters that were also associated with different post-
operative cTnT profiles. Interestingly, gender, ejection fraction,
NYHA category and urgency/emergency, although differently
FIGURE 2 | Evolution of cTnT values in subgroups of patients with a peak of
cTnT of ≥1 ng/mL and occurring ≤6 h (green curve), between >6 to ≤12 h
(blue curve), between >12 and ≤18 h (orange curve), between >18 and ≤24 h
(black curve) and >24 h (red curve). Vertical bars are standard deviations for
the cTnT values. Horizontal bars are standard deviations for the time of blood
sampling.
represented between patients with a max cTnT ≥1 ng/mL, were
not associated with different post-operative cTnT profiles.
All parameters that appeared in this univariate analysis as
differently represented between the early vs. late peak of cTnT, as
well as logitic EuroSCORE were considered for a multivariable
analysis, that was thus conducted to identify the pre-operative
and operative parameters, which could have had an influence
on the time of peak occurrence (Table 3). It appeared that
age (OR: 1.019) and isolated CABG (OR: 1.779) independently
influenced the occurrence of a late elevation of cTnT over
1 ng/ml, whereas isolated valve procedures (OR: 0.685) and
cross-clamp time (OR: 0.993) independently influenced the
occurrence of an early elevation over 1 ng/ml. Interestingly,
parameters which independently influenced the late increase of
cTnT were slightly different in patients whose cTnT remained
below 1 ng/ml (Table 3). Among them, age (OR: 1.023), previous
cardiac surgery (OR: 1.562), pre-operative renal insufficiency
(OR: 1.402), and logistic EuroSCORE (OR: 1.014) had a highly
significant effect (p < 0.005).
Outcomes also varied between patients with early vs. late
elevation of cTnT over 1 ng/ml (Tables 2C, 4A and 4B).
Complications, and especially PMI but also resuscitation, stroke,
death, MACCE or new development of a renal insufficiency were
all significantly associated with both early and late peak of post-
operative cTnT. However, late cTnT peak (>12 h) was associated
with a higher rate of PMI (19.8 vs. 7.2%), death (7.4 vs. 4.4%),
MACCE (32.0 vs. 15.5%) or incidence of a new renal insufficiency
(16.3 vs. 6.7%).
DISCUSSION
In 2000, Carrier et al. suggested that peak of cTnT following
a CABG procedure, occurs around 4–7 h post-reperfusion in a
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TABLE 2A | Patient characteristics according to the post-operative period of cTnT peak occurrence in patients with elevated cTnT course (≥1 ng/mL).
Period of cTnT peak occurrence
≤6 h >6 to ≤12 h >12 to ≤18 h >18 to ≤24 h >24 h p
(n = 22) (n = 366) (n = 176) (n = 171) (n = 218)
Age (y) 59.1 ± 18.2 62.5 ± 14.2 63.9 ± 12.9 67.5 ± 10.3 68.9 ± 10.4 0.000
Female gender (n, %) 3 (13.6) 117 (32.0) 56 (31.8) 62 (36.3) 61 (28.0) 0.742
Diabetes (n, %) 6 (27.3) 50 (13.7) 31 (17.6) 36 (21.1) 54 (24.8) 0.007
Current smoker (n, %) 12 (54.5) 170 (46.4) 81 (46.0) 96 (56.1) 101 (46.3) 0.995
Hypertension (n, %) 9 (40.9) 243 (66.4) 124 (70.5) 141 (82.5) 163 (74.8) 0.000
Dyslipidemia (n, %) 10 (45.5) 183 (50.0) 95 (54.0) 107 (62.6) 139 (63.8) 0.026
Previous PCI (n, %) 0 (0.0) 20 (5.5) 12 (6.8) 25 (14.6) 32 (14.7) 0.000
Previous cardiac surgery (n, %) 3 (13.6) 52 (14.2) 29 (16.5) 19 (11.1) 26 (11.9) 0.031
Last pre-operative creatinine (µmol/L) 89.0 ± 22.1 96.6 ± 75.0 109.3 ± 93.0 114.0 ± 107.1 121.8 ± 123.3 0.000
Coronary artery disease (n, %) 36.4 32.8 42.6 57.3 57.8 0.000
1 coronary artery disease (n, %) 1 (4.5) 21 (5.7) 12 (6.8) 12 (7.0) 22 (10.1)
2 coronary artery disease (n, %) 2 (9.1) 28 (7.7) 15 (8.5) 10 (5.8) 25 (11.5)
3 coronary artery disease (n, %) 5 (22.7) 71 (19.4) 48 (27.3) 76 (44.4) 79 (36.2)
Left main stem stenosis >50 (n, %) 1 (4.5) 17 (4.6) 12 (6.8) 11 (6.4) 22 (10.1) 0.430
Ejection Fraction (n, %) 57.2 ± 11.6 56.5 ± 11.9 57.5 ± 10.5 56.9 ± 11.0 55.3 ± 12.8 0.224
CCS III or IV (n, %) 5 (22.7) 39 (10.7) 25 (14.2) 33 (19.3) 39 (17.9) 0.003
NYHA III or IV (n, %) 11 (50.0) 130 (35.5) 66 (37.5) 56 (32.7) 80 (36.7) 0.679
Urgency 0.270
Emergency (n, %) 9 (40.9) 51 (13.9) 28 (15.9) 17 (9.9) 28 (12.8)
Urgent (n, %) 1 (4.5) 28 (7.7) 14 (8.0) 23 (13.5) 26 (11.9)
Logistic EuroSCORE 22.4 ± 24.9 13.7 ± 16.9 15.9 ± 17.7 12.2 ± 13.9 16.8 ± 19.6 0.623
Note that the p-value refers to the testing for a non-parametric trend among peak cTnT occurrence groups. PCI, percutaneous coronary intervention; CCS, Canadian Cardiovascular
Society classification for angina pectoris; NYHA, New York Heart Association classification for cardiac insufficiency.
subgroup of patients who will not develop a PMI. Conversely,
patients who eventually developed a complication, including
a PMI, presented post-operative values of cTnT that kept
increasing with a peak occurring between 24 and 48 h post-
chest closure (14). This observation was later confirmed by
others (19–21). In the current analysis, we approached the
patients not from the side of their complication but from
the side of their post-operative cTnT profile. We found that
several groups can be defined according to the time of the
peak occurrence. Approximately 40% of the patients with a
post-operative elevation of cTnT over 1 ng/ml had their cTnT
peak occurring before 12 h whereas 60% had a delayed increase
of cTnT with a peak that occurred later than 12 h. Various
time of peak occurrence were also found for those patients
with a maximal post-operative cTnT value that remained below
1 ng/ml. Among these later patients, we found that patient’s
age, history of previous cardiac surgery, pre-operative renal
insufficiency and EuroSCORE were independently associated
with a late increase of TnT. However, only age independently
predicted a late increase over 1 ng/ml whereas the duration
of cross-clamp time had an influence on the early increase
of cTnT values. Interestingly, isolated CABG procedures were
independently associated to a late increase of cTnT whereas
isolated valve procedures were associated to an early peak of
cTnT.
In fact, several factors have been demonstrated or suggested
to influence the post-operative elevation of cTnT values. These
include factors related to the surgical procedure as well as factors
related to the patient himself. For instance, the duration of
cross-clamp time, especially when prolonged over 60min, is
well-known to increase the post-operative values of cTnT (3–
7, 12, 23). In addition, the results of the current study seem
to indicate that this elevation occurs rather in the early post-
operative hours. The type of surgery also seems to play a role.
Indeed, cTnT after isolated CABG procedures are not as elevated
as after valve surgery or interventions combining CABG and
valve surgery. Nesher et al. (1) reported a cTnT value of 0.9 ±
1.5, 1.2 ± 2.9, and 1.3 ± 1.2 ng/ml after isolated CABG, valve
procedures or combination of both, respectively (n = 1,515, 229,
and 174, respectively). Lurati Buse (2) recently reported TnT
values of 0.38 ng/ml (IQR: 0.20–0.71) vs. 0.55 ng/ml (0.31–1.07)
after isolated CABG vs. other procedures. The reason why we
observed an early peak of cTnT after valve surgery as opposed
to a later peak after isolated CABG procedures is not clear but
may reflect a better cardioplegic protection in CABG vs. valve
patients and would fit to the previously mentioned higher level
of post-operative cTnT after valve surgery. In fact, valve surgery
candidates typically present a left ventricular hypertrophy, i.e.,
an increase of their cardiac muscle mass, which in turn could
proportionally increase the post-operative cTnT value (24–26).
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TABLE 2B | Procedure characteristics according to the post-operative period of cTnT peak occurrence in patients with elevated cTnT course (≥1 ng/mL).
Period of cTnT peak occurrence
≤6 h >6 to ≤12 h >12 to ≤18 h >18 to ≤24 h >24 h p
(n = 22) (n = 366) (n = 176) (n = 171) (n = 218)
Isolated CABG (n, %) 2 (9.1) 35 (9.6) 25 (14.2) 49 (28.7) 53 (24.3) 0.000
Number of distal anastomoses 1.8 ± 1.2 2.6 ± 2.0 2.6 ± 1.7 2.8 ± 1.4 2.5 ± 1.4 0.127
Isolated aortic valve (n, %) 3 (13.6) 40 (10.9) 16 (9.1) 14 (8.2) 16 (7.3) 0.028
Isolated mitral valve (n, %) 3 (13.6) 51 (13.9) 15 (8.5) 15 (8.8) 12 (5.5) 0.008
CABG & valve (n, %) 6 (27.3) 65 (17.8) 36 (20.5) 38 (22.2) 47 (21.6) 0.270
Other operation (n, %) 8 (36.4) 175 (47.8) 84 (47.7) 55 (32.2) 90 (41.3) 0.007
Duration of operation (min) 286.0 ± 97.5 265.0 ± 85.0 278.6 ± 93.5 233.3 ± 80.1 252.7 ± 92.1 0.000
ECC time (min) 152.0 ± 49.2 147.6 ± 58.5 148.1 ± 64.8 116.0 ± 52.5 126.1 ± 63.6 0.000
Cross clamp time (min) 98.5 ± 35.3 97.4 ± 40.7 97.4 ± 41.8 76.2 ± 35.2 80.9 ± 38.5 0.000
Defibrillation (n, %) 7 (31.8) 146 (39.9) 69 (39.2) 60 (35.1) 64 (29.4) 0.055
Note that the p-value refers to the testing for a non-parametric trend among peak cTnT occurrence groups. CABG, coronary artery bypass grafting; ECC, extra corporeal circulation.
TABLE 2C | Post-operative outcomes according to the post-operative period of cTnT peak occurrence in patients with elevated cTnT course (≥1 ng/mL).
Period of cTnT peak occurrence
≤6 h >6 to ≤12 h >12 to ≤18 h >18 to ≤24 h >24 h p
(n = 22) (n = 366) (n = 176) (n = 171) (n = 218)
Max. cTnT value (ng/ml)* 2.2 (1.6–2.9) 1.7 (1.6–1.8) 2.1 (1.9–2.3) 1.9 (1.7–2.1) 2.1 (1.9–2.4) 0.000
Max. CK-MB value (µg/L)* 66 (46–94) 44 (41–48) 60 (53–69) 63 (56–72) 72 (64–81) 0.000
Myocardial infarction (n, %) 3 (13.6) 25 (6.8) 22 (12.5) 38 (22.2) 52 (23.9) 0.000
Resuscitation (n, %) 0 (0.0) 12 (3.3) 10 (5.7) 6 (3.5) 10 (4.6) 0.437
Stroke (n, %) 2 (9.1) 23 (6.3) 15 (8.5) 8 (4.7) 27 (12.4) 0.021
Death (n, %) 1 (4.5) 16 (4.4) 11 (6.3) 6 (3.5) 25 (11.5) 0.660
MACCE (n, %) 6 (27.3) 54 (14.8) 43 (24.4) 45 (26.3) 93 (42.7) 0.000
ICU stay (d)* 1.9 (1.3–2.7) 1.5 (1.4–1.6) 1.7 (1.5–2.0) 1.5 (1.3–1.7) 2.2 (1.9–2.5) 0.000
ICU stay >48 h (n, %) 9 (40.9) 107 (29.2) 65 (36.9) 47 (27.5) 110 (50.5) 0.000
New AF (n, %) 4 (18.2) 89 (24.3) 45 (25.6) 45 (26.3) 65 (29.8) 0.047
Max. creatinine value (µmol/L)* 83 (71–99) 91 (87–95) 101 (94–109) 107 (98–116) 116 (107–126) 0.000
New renal insufficiency or new dialysis (n, %) 2 (9.1) 24 (6.6) 21 (11.9) 19 (11.1) 52 (23.9) 0.000
Length of stay (d)* 11 (8–15) 11 (10–12) 11 (10–12) 11 (10–12) 13 (11–14) 0.000
Note that the p-value refers to the testing for a non-parametric trend among peak cTnT occurrence groups. *Calculations are based on the geometric mean and reference ranges.
MACCE, major adverse cardiovascular or cerebrovascular event (as a composite of all-cause mortality, myocardial infarction, or stroke); ICU, intensive care unit.
Non-surgical factors also influence the post-operative
elevation of cTnT values. Age for instance has recently been
shown to be associated with higher cTnT values (27, 28). The
pre-operative renal function has also a clear impact on the
post-operative cTnT values (9–11). In a very recent study (8)
performed in 11,847 patients with chest pain in the emergency
room, the authors observed that reduced estimated glomerular
filtration rate (eGFR) was the strongest predictor of an elevated
troponin level.
A second aspect of our study concerned the clinical relevance
of early vs. late increase of cTnT values in terms of prediction
of post-operative complications. In fact, we observed that it was
rather the elevation over a cut-off value of 1 ng/ml that was
determinant. Nevertheless, it also appeared that an early post-
operative elevation of cTnT–with a peak value occurring before
12 h—followed by a reduction, was associated with a lower rate
of complications, including MI, MACCE and death, as compared
to patients with a late increase of cTnT values. This could be
explained by the influence of the previously mentioned factors
(age, history of previous cardiac surgery, pre-operative renal
insufficiency and EuroSCORE) which all have a clear influence
on the post-operative outcome. Conversely, early peak of cTnT
may rather reflect surgery related factors, such as the duration of
ischemia and the quality of the myocardial protection.
The current study has obviously certain limitations including
the fact that it is a retrospective study. All data were however
prospectively collected, reviewed and completed by a dedicated
team of data managers. Another limitation is the choice of a
cut-off value of cTnT that is associated with an increased risk of
complications. A real cut-off value has indeed not been clearly
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TABLE 3 | Association of preoperative and operative risks with late (>12 h) occurrence of a peak TnT from multivariable analysis, stratified by high (≥1 ng/mL) vs. normal
cTnT.
cTnT <1ng/mL (n = 4,193) cTnT ≥1ng/mL (n = 953)
OR (CI) p OR (CI) p
Age 1.023 (1.016–1.030) 0.000 1.019 (1.007–1.031) 0.002
Diabetes 1.054 (0.888–1.252) 0.547 1.175 (0.805–1.713) 0.403
Previous cardiac surgery 1.562 (1.159–2.104) 0.003 1.267 (0.829–1.936) 0.274
preop. renal insufficiency 1.402 (1.154–1.704) 0.001 1.042 (0.741–1.465) 0.812
coronary artery disease 1.159 (0.956–1.404) 0.133 1.127 (0.810–1.569) 0.477
Logistic EuroSCORE 1.014 (1.007–1.021) 0.000 1.002 (0.993–1.011) 0.672
Isolated CABG 0.810 (0.663–0.991) 0.041 1.779 (1.114–2.839) 0.016
Isolated valve procedure 1.024 (0.830–1.264) 0.824 0.685 (0.471–0.998) 0.049
Cross clamp time 1.003 (1.000–1.006) 0.030 0.993 (0.990–0.997) 0.001
CABG, coronary artery bypass grafting.
TABLE 4A | Univariable association of high peak TnT (≥1 ng/mL) with
post-operative complications, stratified by early TnT peak.
Peak reached ≤12h after surgery
<1 ng/mL ≥1 ng/mL OR (CI)
n (2,978) n (388)
Myocardial infarction (n, %) 4 (0.1) 28 (7.2) 58.2 (20.3–166.8)
Resuscitation (n, %) 7 (0.2) 12 (3.1) 13.7 (5.3–34.9)
Stroke (n, %) 79 (2.7) 25 (6.4) 2.5 (1.6–4.0)
Death (n, %) 5 (0.2) 17 (4.4) 27.2 (10.0–74.3)
MACCE (n, %) 86 (2.9) 60 (15.5) 6.2 (4.3–8.7)
ICU stay >48 h (n, %) 342 (11.5) 116 (29.9) 3.3 (2.6–4.2)
New renal insufficiency (n, %) 50 (1.7) 26 (6.7) 4.2 (2.6–6.8)
The p-value of each association is ≤0.001. MACCE, major adverse cardiovascular or
cerebrovascular event (as a composite of all-cause mortality, myocardial infarction, or
stroke); ICU, intensive care unit.
defined yet however several previous publications, including one
from our group, have found a cut-off value around 1 ng/ml, the
cut-off value we eventually set, to be reasonably representative
of the reality in most cardiac surgery centers (1, 12, 15, 22, 29).
Another aspect that was not taken into account is the level
of cTnT increase. Although it looks like the average value of
the peak was very similar in all time categories, it would be
reasonable to expect a higher risk of post-operative complications
in patients with higher cTnT values. Finally, the type of ECC
and cardioplegia was different for isolated CABG as for other
procedures. The combination of MECC and CardioplexolTM is
indeed especially advantageous in isolated CABG and could thus
have had an effect on the overall results presented here (30).
As opposed to several articles which focus on specific
subgroups of patients, we based the design of our study on
the fact that the elevation of cTnT and other markers of
perioperative myocardial damage is currently assessed without
distinction between subgroups. In that sense, we thought of
including a general population of cardiac surgery patients that
would also be representative of the activity in most centers. It
TABLE 4B | Univariable association of high peak TnT (≥1 ng/mL) with
post-operative complications, stratified by late TnT peak.
Peak reached >12h after surgery
<1 ng/mL ≥1 ng/mL OR (CI)
n (1,215) n (565)
Myocardial infarction (n, %) 9 (0.7) 112 (19.8) 33.3 (16.8–66.3)
Resuscitation (n, %) 13 (1.1) 26 (4.6) 4.5 (2.3–8.8)
Stroke (n, %) 56 (4.6) 50 (8.8) 2.0 (1.4–3.0)
Death (n, %) 19 (1.6) 42 (7.4) 5.1 (2.9–8.8)
MACCE (n, %) 79 (6.5) 181 (32.0) 6.8 (5.1–9.0)
ICU stay >48 h (n, %) 239 (19.7) 222 (39.3) 2.6 (2.1–3.3)
New renal insufficiency (n, %) 71 (5.8) 92 (16.3) 3.1 (2.3–4.3)
The p-value of each association is ≤0.001. MACCE, major adverse cardiovascular or
cerebrovascular event (as a composite of all-cause mortality, myocardial infarction, or
stroke); ICU, intensive care unit.
is true that doing so could have introduced some bias. On the
other hand, with a collection of more than five thousands of
patients and, we believe, data of high quality, it was possible
to run a multivariable analysis including a relatively large
series of parameters including subgroups. Finally, it is with
this general approach that we could identify some of these
subgroups as being associated with different post-operative
TnT profiles. For instance isolated CABG procedures appeared
related to rather late increase of TnT whereas isolated valve
procedures were more related to early peak of TnT. Nevertheless,
this information must be interpreted with caution considering
the fact that the cut-off value between normal and elevated
cTnT groups clearly distinguished two different profiles of
patients.
The fact that we cannot provide reliable baseline (pre-
operative) values of cTnT and that we cannot totally exclude
that some patients had already an elevated starting value prior
to surgery can also be seen as a limitation. However, all patients
with documented MI during the 8 days prior to surgery have
been excluded. In addition and according to recent published
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papers on cTnT in unstable angina (31), we estimate that
even in patients with a possible pre-operative cTnT elevation,
this value would most probably still be under 0.1 ng/ml (100
ng/L). For cardiac surgical patients however, it is well-known
that the surgical trauma itself contributes to a much higher
elevation of cTnT values. In that sense, we estimate that a
possible preoperative elevation of cTnT should be considered
as neglectable as compared to the inevitable and much higher
elevation that follows the surgical trauma. More importantly, we
think it is reasonable to estimate that the preoperative cTnT value
did not have an influence on the profile of post-operative cTnT
elevation.
Our analysis focused on post-operative cTnT. However,
several centers use rather troponin I (TnI) or CK-MB as marker
of post-operative myocardial damage. We have collected CK-MB
values for the same patients and at the same times and although
CK-MB was not studied as extensively as cTnT, data displayed in
Tables 1C, 2C seem to follow a similar pattern as cTnT.Whereas,
similar results would be obtained for TnI cannot be guaranteed
and should thus be studied separately. Basically however, values
of TnI and cTnT, although not directly proportional tend to
follow similar profiles. In that sense, it could reasonably be
expected that the results would be similar for TnI.
In conclusion, it seems that besides the severity of post-
operative cTnT elevation, the time of peak expression is also of
importance. We showed that early peaks of post-operative cTnT
values rather reflect difficulties that occurred during the surgical
procedure whereas later increases are more related to patients’
intrinsic factors. Interestingly, both early and late elevations of
cTnT are associated with an increased risk of complications but
this risk appears critically higher in case of a late elevation.
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